However, many of the remissions are not proving durable. Current page 1 Next page next Last page last » Print Page. This is the same state of play as at the Asco data cutoff. Presentations Allogene June 2023 Corporate Presentation June 5, 2023. (Nasdaq:KITE) today announced new data presentations from multiple studies related to its lead investigational candidate, axicabtagene ciloleucel, at the American Association of Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017. So far so good, and it must also be stressed that safety remains relatively clean: among grade 3 events there is just one cytokine release syndrome and two neurotoxicity cases. And 27 of those 38 responses are complete. All 31 patients previously detailed had gone into remission, and so have the extra seven patients now presented. presentation shall not constitute an offer to sell or the solicitation of an offer to buy. SANTA MONICA, Calif., Ap- Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy products for the. (Kite,we,us,or our),they are forward-looking statements reflecting management’scurrent beliefs and. This was on the basis of efficacy in line with Carvykti in an arguably harder-to-treat population, with possibly better safety to boot.Īt Ash it is adding seven patients to bring the evaluable dataset to 38 as of an October 31 cutoff. Enter your email to get Kite Pharmas Company profile in your inbox 5+ Funding Rounds 10+ Investors 2.6K+ Competitors. To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc.
The last time Arcellx presented CART-ddBCMA data, at Asco in June, it argued that the project, which is autologous but uses an artificial binding domain to hit BCMA, had “best-in-class potential”. Former Kite Pharma Executive Responsible for the Development and. The Gilead deal adds a key endorsement.īeing competitive in this space is especially hard given the huge number of BCMA-targeting projects in development, and the added availability as of October of J&J’s Tecvayli, a T-cell engaging MAb. Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in. J&J’s approved rival BCMA-directed Car-T therapy, Carvykti, has set a high bar which, once again, CART-ddBCMA seems to have met.
Kite pharma investor presentation update#
Friday’s licensing deal saw the big biotech hand across $225m in cash and make a $100m equity investment for rights to the project.Īn investor update made available ahead of Arcellx’s Ash poster on Sunday sheds more light on the latest cut of the phase 1 CART-ddBCMA study that secured Gilead as a partner. With Arcellx’s CART-ddBCMA maintaining its 100% track record of putting multiple myeloma patients into remission, according to data being presented at Ash, Gilead heard enough to sign on the dotted line.
0 kommentar(er)
